Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
Verve Therapeutics announced FDA clearance of its IND application for VERVE-101, a gene-editing treatment targeting PCSK9 to lower LDL-C in HeFH patients. The heart-1 trial, evaluating VERVE-101's safety and efficacy, progresses with interim data to be presented at AHA's 2023 Scientific Sessions.
Reference News
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
Verve Therapeutics announced FDA clearance of its IND application for VERVE-101, a gene-editing treatment targeting PCSK9 to lower LDL-C in HeFH patients. The heart-1 trial, evaluating VERVE-101's safety and efficacy, progresses with interim data to be presented at AHA's 2023 Scientific Sessions.